About this item:

19 Views | 14 Downloads

Author Notes:

mzwick@emory.edu

First and foremost, we want to thank the families and individuals with Down syndrome for contributing their time and effort towards this project.

C.E.T., A.M.H., M.E.Z., S.L.S., M.P.E., D.J.C., and J.G.M. were all involved in the conception and design of the work presented in this manuscript. C.E.T. and A.M.H. jointly drafted the manuscript, with all authors reviewing and providing feedback on the manuscript. Ascertainment of the samples and phenotype assessment of individuals with DS were accomplished through the efforts of S.L.S., C.L.M., T.C.R., K.J.D., G.T.C., R.H.R, P.J.G., J.E.O., D.C.B., L.W., C.L.C., I.P.M., and E.G. (sponsor of PCGC-approved ancillary project). H.R.J., D.J.C., and B.L.R. performed mapping and variant calling for the WES and WGS datasets, and together with C.E.T. performed QC of these data. C.E.T. performed the gene- and pathway-level (SKAT) analyses. H.C. and J.O. were involved in the initial phase of these datasets and helped to set the framework for these analyses. H.J.C., B.D.K., A.J.A., and E.G. generated the GWAS summary results used as training data for the PRS analyses. A.M.H. performed imputation of the array genotype data, and QC and analyses for the PRS application.

The authors declare no competing interests.

Subject:

Research Funding:

The DS Heart Project (R.H.R.) was a collaborative project supported through several National Institutes of Health awards: R01 HL092981-01A1 (M.E.Z.) and R01 HL083300 (R.H.R.) from NIH/National Heart, Lung, and Blood Institute; R01 HD38979 (S.L.S.) from NIH/National Institute of Child Health and Human Development and GM117946 (M.P.E.) from NIH/National Institute of General Medical Sciences. Whole exome sequencing services that were done as part of the DSHP were provided by the University of Washington, Department of Genome Sciences under U.S. Federal Government contract number HHSN268201100037C (D. Nickerson). Whole genome sequencing services were supported by the Emory Integrated Genomics Core (EIGC) and the Emory Integrated Computational Core (EICC), which are subsidized by the Emory University School of Medicine and are part of the Emory Integrated Core Facilities. Partial support to M.E.Z was also provided by the Georgia Clinical & Translational Science Alliance which is funded by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award number UL1TR002378. The American Heart Association Western States Affiliate provided support to H. Corbitt (grant number 16PRE30190012). I.P. Moskowitz was supported by the following grants: R01 HL092153, R01 HL124836, and R01 HL126509. We thank Dr. Eleanor Feingold for providing the chromosome 21 genotype calls for the SNP Affymetrix dataset. We thank the Pediatric Cardiac Genomic Consortium (PCGC) for its contributions to this work, and recognize E.G. as sponsor of the PCGC-approved ancillary project. The PCGC provided samples for the WGS study which were collected under the auspices of the National Heart, Lung, and Blood Institute’s Bench to Bassinet Program (https://benchtobassinet.com). Support for the PCGC is provided through grants from National Heart, Lung, and Blood Institute (U01-HL098188, U01-HL098147, U01-HL098153, U01-HL098163, U01-HL098123, U01-HL098162). We would like to thank Marianne S. Hird at the PCGC for her help on this project throughout its administration. The Agopian et al. (2017) GWAS discovery dataset used for the PRS analyses was generated with support from an Institutional Development Fund to The Center for Applied Genomics from The Children’s Hospital of Philadelphia. Further support was provided by the National Heart, Lung, and Blood Institute P50-HL74731 (E.G.) and the National Center for Research Resources M01-RR-000240, RR024134 [now the National Center for Advancing Translational Sciences UL1TR000003) (E.G.). The Cordell et al. (2013) GWAS discovery data used for the PRS analyses were generated with support from the British Heart Foundation, Heart Research UK, Wellcome Trust and European Union. B.D.K. is supported by a British Heart Foundation Personal Chair. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keywords:

  • Genomic analysis
  • DNA sequencing
  • Genetic variation
  • Aneuploidy
  • Cardiovascular genetics
  • Congenital heart defects

Identifying genetic factors that contribute to the increased risk of congenital heart defects in infants with Down syndrome

Show all authors Show less authors

Tools:

Journal Title:

Scientific Reports

Volume:

Volume 10

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

Atrioventricular septal defects (AVSD) are a severe congenital heart defect present in individuals with Down syndrome (DS) at a > 2000-fold increased prevalence compared to the general population. This study aimed to identify risk-associated genes and pathways and to examine a potential polygenic contribution to AVSD in DS. We analyzed a total cohort of 702 individuals with DS with or without AVSD, with genomic data from whole exome sequencing, whole genome sequencing, and/or array-based imputation. We utilized sequence kernel association testing and polygenic risk score (PRS) methods to examine rare and common variants. Our findings suggest that the Notch pathway, particularly NOTCH4, as well as genes involved in the ciliome including CEP290 may play a role in AVSD in DS. These pathways have also been implicated in DS-associated AVSD in prior studies. A polygenic component for AVSD in DS has not been examined previously. Using weights based on the largest genome-wide association study of congenital heart defects available (2594 cases and 5159 controls; all general population samples), we found PRS to be associated with AVSD with odds ratios ranging from 1.2 to 1.3 per standard deviation increase in PRS and corresponding liability r2 values of approximately 1%, suggesting at least a small polygenic contribution to DS-associated AVSD. Future studies with larger sample sizes will improve identification and quantification of genetic contributions to AVSD in DS.

Copyright information:

© The Author(s) 2020, corrected publication 2021

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote